- Home
- VOD vs BIIB Comparison
VOD vs BIIB Comparison
Compare VOD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOD
- BIIB
- Stock Information
- Founded
- VOD 1984
- BIIB 1978
- Country
- VOD United Kingdom
- BIIB United States
- Employees
- VOD N/A
- BIIB N/A
- Industry
- VOD Telecommunications Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- VOD Telecommunications
- BIIB Health Care
- Exchange
- VOD Nasdaq
- BIIB Nasdaq
- Market Cap
- VOD 22.6B
- BIIB 19.9B
- IPO Year
- VOD 1988
- BIIB 1991
- Fundamental
- Price
- VOD $9.25
- BIIB $118.39
- Analyst Decision
- VOD Sell
- BIIB Buy
- Analyst Count
- VOD 1
- BIIB 27
- Target Price
- VOD N/A
- BIIB $201.26
- AVG Volume (30 Days)
- VOD 14.2M
- BIIB 1.5M
- Earning Date
- VOD 05-20-2025
- BIIB 05-01-2025
- Dividend Yield
- VOD 7.69%
- BIIB N/A
- EPS Growth
- VOD N/A
- BIIB 26.39
- EPS
- VOD 0.11
- BIIB 10.12
- Revenue
- VOD $41,278,161,929.00
- BIIB $9,816,400,000.00
- Revenue This Year
- VOD $6.79
- BIIB N/A
- Revenue Next Year
- VOD $3.05
- BIIB N/A
- P/E Ratio
- VOD $8.36
- BIIB $11.70
- Revenue Growth
- VOD 5.15
- BIIB 1.59
- 52 Week Low
- VOD $8.00
- BIIB $110.04
- 52 Week High
- VOD $10.39
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- VOD 47.81
- BIIB 42.43
- Support Level
- VOD $9.53
- BIIB $115.86
- Resistance Level
- VOD $9.74
- BIIB $125.34
- Average True Range (ATR)
- VOD 0.13
- BIIB 3.49
- MACD
- VOD -0.01
- BIIB 0.70
- Stochastic Oscillator
- VOD 11.29
- BIIB 30.91
About VOD Vodafone Group Plc
Vodafone operates mobile and fixed-line networks and businesses in more than 20 countries. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns a cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK it acts as a mobile operator and is attempting a merger with CK Hutchison. In 2024 Vodafone divested its Spanish and Italian divisions, given their low returns on invested capital.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.